vitx الله اعلم الى اين ستذهب

[وائل خيرى مطاوع]

واللو 1.125$

شوف انا صايده من وين

http://69.93.139.106/~indexsi/vb/showthread.php?t=20441

والله شكله واقف لدعم 1.15

ولكن اتوقع ارتداه من 1.04$

ولو كسرها يبقى هيرتد من 0.95$

والله اعلم

وفقنى الله واياكم

[ELASBANI]

أهلا اخ وائل ...
طلة حسنة ...وبالتوفيق

[وائل خيرى مطاوع]

لك وحشة انت والحبايب

كلكم والله

الله يرزقنا جميعا

وفقنى الله واياكم

[island]

الرسالة الأصلية كتبت بواسطة island
هلا والله بالصديق الغالي الاسباني
بالفعل مجال المضاربة مربحة وخصوصا في الاسهم اللي ذبذبتها خلال اليوم عالية
تابع سهم ibd السعر 64 سنت انشالله مكسب من 30 الى 50 % تحياتي لك

IBD
عزيزي الاسباني 85 سنت مبروك احتمال نشوف 1 دولار

[abu faisal]

الرسالة الأصلية كتبت بواسطة yousif
طمرت عليها 1.32 الله كريم

الخبر قوي جدا جدا جدا

انشاء الله فوق

علمنا اذا بعت السهم
والاناوي نشوف العشره دولار

[المتسابق]

مع المتابعه اليوميه .............


يمكن مع الصبر يقوم هذا السهم بتعويض كل شيء....

يمكن ..........















قول ان شاء الله .....





























ويارب قريبا ................






























آميييييييييييييييييييييييين ................





















سلالالالالالالالالالالالام

[Pivotrend]

لم أرى أحد يحب يدخل في دهاليز البني ستوك و أخبارها مثلك يا يوسف

[abu faisal]

Shares of V.I. Technologies (VITX:Nasdaq - commentary - research) were among the best-performing health and pharmaceutical stocks Thursday, rising 69.6% after the company's merger partner received fast-track status from the Food and Drug Administration for its HIV drug.

Privately held Panacos Pharmaceuticals, which plans to merge with V.I during the first quarter of 2005, said the oral drug was well tolerated during phase Ia and phase Ib studies. Full results will be presented at a conference in February. In December, the company initiated a phase IIa trial of PA-457. Results from the trial are expected during the second quarter of 2005. Shares traded up 48 cents to $1.17.



بعد النظر الى هذا الخبر بتعمق استنتجت الاتي
اصطياد السهم خلال الاسبوع القادم او الي بعده بعد ان يبدا في النزول سعر الدخول من 0.65 الى 0.8
سوف يكون لهذا السهم قفزتان في خلال الثلاث الاشهر القادمه
واحده عند اعلان نتائج اختبارات الدواء الكامله في شهر فبراير
الثانيه عند اعلان الاندماج الرسمي مع شركة بانكوس للادويه في شهر ابريل او حولها
هذا وجهة نضري
اما الاستثمار طويل الاجل خلال سنتين واكثر "الى ان يتم اخذ الموافقه النهائيه لدواء واثبات انه فعال"
فهذاهدفه بعيد جدا لو فعلا اثبت نجاح الدواء فسعر السهم سوف يصل الى 20 دولار اقل شي
وخذ في عين الاعتبار ان الدواء ممكن ان يفشل او ان ترفضه منضمة الغذاء والدواء الامريكيه
وساعتها الله لايقدر السهم سوف ينهار

[ELASBANI]

FirstAlert 1/7: In Your Face, Bear, Says a Bull


Jan 7, 2005 (financialwire.net via COMTEX) -- (FinancialWire) Market guru
Charles Payne says he wants to go on record as "still being very optimistic
about 2005," noting that today's unemployment numbers, whicpered at less
than 175,000, will yet show if there will be another bump on the way. "The
market is oversold by many measures including common sense. That said, the Dow
Jones has to find a way to close above 10,682, and then get north of 10,840
before jittery investors will have the nerve to jump in. One of the reasons I'm
optimistic about the prospects for 2005 is that I see serious reemergence of the
average investor. Yet, already, that assumption is being challenged, as it will
take professional investors and the speculation crowd to do some heavy lifting
from here to trigger the market higher. On the downside, an adverse reaction to
the jobs data could land the Dow Jones around 10,440, which is a must hold
support point," said Payne.

The Investrend Earnings Calendar reveals Great Atlantic & Pacific (NYSE: GAP),
expected at $(1.19) versus $(1.21) a year ago. Top advancers Thursday were VI
Technologies (NASDAQ: VITX), which exploded 69.57%, Aastrom Bioscience (NASDAQ:
ASTM), up 16.67%, and Western Wireless (NASDAQ: WWCA), ahead 15.16%,

The Investrend Economics Calendar lists Employment Report for December at 8:30-
a.m., and

Consumer Credit for November at 3 p.m.

The Investrend Events Calendar showcases TIVO, TXN, GTW at CEA 2005
International, and the US Fed's Ferguson speaking on Productivity and Job Growth
at ASSA, and the US Fed's Santomero speaking to Allied Social Science
Association today and on Banking Regulation tomorrow in Philadelphia.

The Investrend Money Index is an indicator of the depth of market direction or
indirection. While not always including the same stocks, the NYSE / NASDAQ 50
Most Actives indicate the direction in which the mass of money is flowing. Last
session's trading showed 30 advancers versus 20 decliners. The advancers were
led by VI Technologies (NASDAQ: VITX), which exploded 69.57%, Aastrom Bioscience
(NASDAQ: ASTM), up 16.67%, Western Wireless (NASDAQ: WWCA), ahead 15.16%, and
Transmeta Corp. (NASDAQ: TMTA), up 13%. Decliners were led by Symantic Corp (NASDAQ: SYMC), down 7.43%, and Veritas Software (NASDAQ: VRTS), off 6.92%
For up-to-the-minute news, features and links click on
http://www.FinancialWire).net

[abu faisal]

هلا اخوي الاسباني
انشاء الله يكون هذي السنه سنة بويلش

انا تخلصت من السهم في البري ماركت بنفس سعر الشراء وذلك لاني اعتقد اني سوف اصيده الاسبوع القادم بي اقل من الدولار

انضر الى iso عليها حركه في البري ماركت وارتفاع 30% بسبب انضمام رئيس جديد الى الشركه

[ELASBANI]

الرسالة الأصلية كتبت بواسطة abu faisal
هلا اخوي الاسباني
انشاء الله يكون هذي السنه سنة بويلش

انا تخلصت من السهم في البري ماركت بنفس سعر الشراء وذلك لاني اعتقد اني سوف اصيده الاسبوع القادم بي اقل من الدولار

انضر الى iso عليها حركه في البري ماركت وارتفاع 30% بسبب انضمام رئيس جديد الى الشركه

Thank you ... I bought this stock ISO yesterday for the first time 0.36 after a friend asked me about it in OSAMA's Muntadah
I will wait the open

[ممدوح]

حتى لو يقفل القاب لتحت فمؤشرات السهم تفيد الاراتداد القوي
و2 دولار بالنسبة لي مضمونة ان شاء الله


للمتابعة الجادة

[maker]

اذا كسر 1.18 فسوف يتجه الى 1.07

[ELASBANI]

الرسالة الأصلية كتبت بواسطة maker
اذا كسر 1.18 فسوف يتجه الى 1.07

I will BUY there 1.07
after sold 1.27
regards

[ممدوح]

الرسالة الأصلية كتبت بواسطة maker
اذا كسر 1.18 فسوف يتجه الى 1.07

حتى لو قفل 0.75
لا استبعد يفتح بكرة دولارين


وعلى كل الاحوال هو سهم استثماري ممتاز واحبار الشركة عسل وسعرها رخيص
والياهو معطيها هدف 8 دولار يا اخوان
انا لن ابيع وسأظل ازود كمياتي مع كل نقطة دعم


ممدوح

[maker]

بارك الله فيك يا أخي ممدوح00
اعتقد ان السهم في طريقه لمزيد من الهبوط في الفترة القادمة

[ELASBANI]

الرسالة الأصلية كتبت بواسطة ELASBANI
I will BUY there 1.07
after sold 1.27
regards

وتم التنفيذ
الادنى 1.06

اخلر تداول 1.12

[abu faisal]

الرسالة الأصلية كتبت بواسطة ELASBANI
وتم التنفيذ
الادنى 1.06

اخلر تداول 1.12

انا نفذت على 1.08
وبعته بعده بي 5 دقايق على 1.11

السهم ممتاز استثماري
ولكن مادام اني ممكن اخذه بسعر اقل لماذااقف مكتوف الايدي؟
امس تعلقت فيه على 1.26
اليوم صرفته في البري ماركت بنفس السعر

اتوقع السبوع لقادم يكسر 1 دولار نزول مالم ينزل اخبار اخرا

[ELASBANI]

ابوفيصل
:fu: :fu: :cash:

[abu faisal]

ماسبب الصعود المفاجئ الليله؟ هل من اخبار

[ELASBANI]

لا أخبار
فقط مضاربات وثلاث ايام نزول صحح بها الصعود القوى
الآن الى المضاربات والتلاعب ...
تحية

[ممدوح]

الرسالة الأصلية كتبت بواسطة yousif
وافق الfda على المرحله الثانيه من دواء علاج الايدز وبسرعه وستدخل المرحله

الثالثه والاخيره للدواء السهم لايوجد له اي تصور او حدود

10$ او 15$ او اكثر

والله يا يوسف ان السهم يستحق المتابعة الجادةالشراء على المدى الطويل
تحياتي

[ALBRENS]

Market Pulse Breaking News Alert for Thursday, January 13, 2005: LFTC - Lifestream's CEO to Testify at FDA Hearing Considering Over-the-Counter Petition for Cholesterol Lowering Drugs!


Market Wire - Thursday, January 13, 2005

--------------------------------------------------------------------------------

ATLANTA, GA -- (MARKET WIRE) -- 13-01-2005 -- Market Pulse News Alert for this AM, Stocks to Watch are: Lifestream Technologies, Inc. (OTC BB: LFTC), Myriad Genetics Inc. (NASDAQ: MYGN), V.I. Technologies, Inc. (NASDAQ: VITX), and eBay Inc. (NASDAQ: EBAY).
Investors need to be watching Lifestream Technologies, Inc. (OTC BB: LFTC) this AM! Lifestream develops, markets and sells a line of smart card-enabled healthcare diagnostic devices. Lifestream has developed and currently markets a line of cholesterol monitors that provide test results in three minutes for at-home use by health conscious consumers and at-risk medical patients. Lifestream just had excellent news out before today's opening bell regarding their CEO being scheduled to testify at the FDA hearing considering an over-the-counter petition for cholesterol lowering drugs! This could be great news for investors!

Lifestream Technologies, Inc. (OTC BB: LFTC), a leading supplier of cholesterol monitors, is scheduled to testify at the FDA hearing considering an over-the-counter petition for cholesterol lowering drugs. Christopher Maus will address the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) during the public comment period on Friday morning, January 14.

"Lifestream's home cholesterol monitor can have a material impact in the FDA's consideration of this petition," said Maus. "I look forward to this opportunity to address any testing concerns the FDA may have, as the benefit of home testing on an individual's effort to take control by personal health management is acknowledged. With Lifestream's affordable, easy and accurate suite of testing products, it is well positioned to support the public's desire to take control of their cholesterol levels. We support government and industry efforts to give more control of preventive health care decisions to individuals."

"Lifestream's new cholesterol monitor with Health Risk Assessment takes testing one step further by giving an individual the ability to understand combined risk factors and the effects those factors may have on their heart health as defined in the NCEP ATP III guidelines," Maus stated. "Recently cleared by the FDA, Lifestream's cholesterol monitor with HRA supports efforts to expand cholesterol management programs. The NCEP ATP III recommends home testing as an important tool for individuals as part of their professional healthcare program. Regardless of an individual's choice of lifestyle changes or the use of prescriptive or non-prescriptive therapies, monitoring cholesterol is a key factor for meaningful outcomes."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

In addition to the professional monitor, the Company's product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.

Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern™ Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

Stocks acting well as of late include: Myriad Genetics Inc. (NASDAQ: MYGN), V.I. Technologies, Inc. (NASDAQ: VITX), and eBay Inc. (NASDAQ: EBAY).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: Lifestream Technologies, Inc. compensation from a third party: three million free trading shares of stock in Lifestream Technologies, Inc., already delivered from a third party. An additional three million restricted shares are pending from Lifestream Technologies, Inc. To date, MP has sold three million shares of stock in Lifestream Technologies, Inc. for proceeds totaling ninety five thousand dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market Pulse News Alert is a division of MP.



Contact:

[ابو الفيصل]

اخوى البرنس عطنا الزبده الخبر زين ولا شين
وكذلك الخبر طلع قبل او بعد اقفال السوق
وشكرا لك مقدما

[ALBRENS]

الرسالة الأصلية كتبت بواسطة ابو الفيصل
اخوى البرنس عطنا الزبده الخبر زين ولا شين
وكذلك الخبر طلع قبل او بعد اقفال السوق
وشكرا لك مقدما

هلا ابو فيصل انا هم مثلك ابي الزبدة

[المتسابق]

وبالرغم من ان مرض الايدز عقاب من الله دون ادني شك لكن الرحمة من الله موجوده

المهم التقييم المستمر
مع وضع هدف سعري للسهم
لمن يحب ان يقطف ....بالنسبه لي وهذا الشيء شخصي

السهم لن يغادر المحفظه الا بتأشيره ....ليه...!!!!
العلاج في المرحلة الثانيه كما ذكر سابقا ...
والمرحلة الثالثه لها ثمارها ...
سلالالالالالالالالالالالالالالالام

[ممدوح]

يوسف
هل سيؤثر هذا الخبر على حركة السهم؟؟؟

المرة دي انفلونزا الطيوووور
http://www.cnn.com/2005/WORLD/asiapc...oll/index.html

[ممدوح]

الرسالة الأصلية كتبت بواسطة yousif
وافق الfda على المرحله الثانيه من دواء علاج الايدز وبسرعه وستدخل المرحله

الثالثه والاخيره للدواء السهم لايوجد له اي تصور او حدود

10$ او 15$ او اكثر

للمتابعة وبداية تكون ايجابي ان شاء الله

[abu faisal]

اخواني الكرام ماهو السعر المناسب لشراء هذا الاسبوع هل نطلبه على 0.91؟

للمعلوميه سوف احتفض بالسهم مدة شهرين الى اعلان نتائج اختبار الدواء كامله للمرحله الثانيه او اعلان اندماج الشركتين رسميا

شكرا لكم

[ELASBANI]

الرسالة الأصلية كتبت بواسطة abu faisal
اخواني الكرام ماهو السعر المناسب لشراء هذا الاسبوع هل نطلبه على 0.91؟

للمعلوميه سوف احتفض بالسهم مدة شهرين الى اعلان نتائج اختبار الدواء كامله للمرحله الثانيه او اعلان اندماج الشركتين رسميا
شكرا لكم

أخى ابوفيصل ...
السلام عليكم .. لا يفتى ومالك ( الاسبانى ) فى المدينة بالنسبة لهذا السهم ..(بمساعدة يوسف طبعا)
السهم يوم 28 فبراير القادم عنده قرار استمراريته بالنازداك ...
السهم ان وصل هناك اشترية ولو اشتريت على 1 جيد أيضا ...
أعتقد السهم سيواصل تحركاته المشابهة للحالية حتى نهاية الشهر وان طار قبلها لسبب ما فسوف يحتفظون بذلك الى بعد التاريخ ...
اعتقادى انهم سيبقوه قرب ال 1.20 فى تلك الايام ..
لك تحياتى ..